Multiple efforts have focused on targeted therapeutic approaches for SOD1-related ALS (ClinicalTrials.gov: NCT01041222: SOD1Rx [14]; NCT00706147: Arimoclomol [15]; NCT01083667: Pyrimethamine [16]). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.